• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对新型冠状病毒肺炎(COVID-19)诊断、治疗及疫苗接种方面近期进展的快速综述。

A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19.

作者信息

Umakanthan Srikanth, Chattu Vijay Kumar, Ranade Anu V, Das Debasmita, Basavarajegowda Abhishekh, Bukelo Maryann

机构信息

Department of Paraclinical Sciences, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago, West Indies.

Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G2C4, Canada.

出版信息

AIMS Public Health. 2021 Feb 1;8(1):137-153. doi: 10.3934/publichealth.2021011. eCollection 2021.

DOI:10.3934/publichealth.2021011
PMID:33575413
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7870385/
Abstract

COVID-19 is caused by SARS-CoV-2, which originated in Wuhan, Hubei province, Central China, in December 2019 and since then has spread rapidly, resulting in a severe pandemic. The infected patient presents with varying non-specific symptoms requiring an accurate and rapid diagnostic tool to detect SARS-CoV-2. This is followed by effective patient isolation and early treatment initiation ranging from supportive therapy to specific drugs such as corticosteroids, antiviral agents, antibiotics, and the recently introduced convalescent plasma. The development of an efficient vaccine has been an on-going challenge by various nations and research companies. A literature search was conducted in early December 2020 in all the major databases such as Medline/PubMed, Web of Science, Scopus and Google Scholar search engines. The findings are discussed in three main thematic areas namely diagnostic approaches, therapeutic options, and potential vaccines in various phases of development. Therefore, an effective and economical vaccine remains the only retort to combat COVID-19 successfully to save millions of lives during this pandemic. However, there is a great scope for further research in discovering cost-effective and safer therapeutics, vaccines and strategies to ensure equitable access to COVID-19 prevention and treatment services.

摘要

2019冠状病毒病(COVID-19)由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起,该病毒于2019年12月起源于中国中部湖北省武汉市,此后迅速传播,导致了一场严重的大流行。受感染患者会出现各种非特异性症状,这就需要一种准确、快速的诊断工具来检测SARS-CoV-2。接下来是对患者进行有效的隔离,并尽早开始治疗,治疗方法包括支持性治疗以及使用特定药物,如皮质类固醇、抗病毒药物、抗生素和最近引入的康复期血浆。开发一种有效的疫苗一直是各国和研究公司面临的持续挑战。2020年12月初,在所有主要数据库(如医学在线/医学期刊数据库(Medline/PubMed)、科学引文索引(Web of Science)、Scopus数据库以及谷歌学术搜索引擎)中进行了文献检索。研究结果在三个主要主题领域进行了讨论,即诊断方法、治疗选择以及处于不同开发阶段的潜在疫苗。因此,一种有效且经济的疫苗仍然是成功抗击2019冠状病毒病、在这场大流行期间拯救数百万人生命的唯一对策。然而,在发现具有成本效益且更安全的治疗方法、疫苗以及确保公平获得2019冠状病毒病预防和治疗服务的策略方面,仍有很大的进一步研究空间。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d8/7870385/b1065613190a/publichealth-08-01-011-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d8/7870385/237c4ea00025/publichealth-08-01-011-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d8/7870385/b1065613190a/publichealth-08-01-011-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d8/7870385/237c4ea00025/publichealth-08-01-011-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d8/7870385/b1065613190a/publichealth-08-01-011-g002.jpg

相似文献

1
A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19.对新型冠状病毒肺炎(COVID-19)诊断、治疗及疫苗接种方面近期进展的快速综述。
AIMS Public Health. 2021 Feb 1;8(1):137-153. doi: 10.3934/publichealth.2021011. eCollection 2021.
2
Insights into Novel Coronavirus Disease 2019 (COVID-19): Current Understanding, Research, and Therapeutic Updates.对 2019 年新型冠状病毒病(COVID-19)的深入了解:当前的认识、研究和治疗进展。
Recent Pat Biotechnol. 2022;16(1):35-63. doi: 10.2174/1872208315666210805152122.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants.新型冠状病毒2年15个月的临床经验:治疗方法与辅助剂的文献综述
Antioxidants (Basel). 2021 May 31;10(6):881. doi: 10.3390/antiox10060881.
5
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19(Sars-Cov-2)的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
6
Current Challenges for the Effective Management of the COVID-19 Pandemic.有效管理 COVID-19 大流行的当前挑战。
Adv Exp Med Biol. 2021;1353:131-149. doi: 10.1007/978-3-030-85113-2_8.
7
An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.关于在疫情爆发情况下治疗新型冠状病毒(SARS-CoV-2)的新兴治疗和预防策略的循证系统评价。
J Basic Clin Physiol Pharmacol. 2020 Sep 14;31(6):jbcpp-2020-0113. doi: 10.1515/jbcpp-2020-0113.
8
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.新型冠状病毒病 2019(COVID-19)的病理生理学、传播、诊断和治疗:综述。
JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
9
Therapeutic potential of green tea catechin, (-)-epigallocatechin-3--gallate (EGCG) in SARS-CoV-2 infection: Major interactions with host/virus proteases.绿茶儿茶素(-)-表没食子儿茶素-3-没食子酸酯(EGCG)在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染中的治疗潜力:与宿主/病毒蛋白酶的主要相互作用
Phytomed Plus. 2023 Feb;3(1):100402. doi: 10.1016/j.phyplu.2022.100402. Epub 2022 Dec 30.
10
Nanotechnology-Based Approach to Combat Pandemic COVID 19: A Review.基于纳米技术对抗新型冠状病毒肺炎的方法:综述
Macromol Symp. 2021 Jun;397(1):2000336. doi: 10.1002/masy.202000336. Epub 2021 Jun 17.

引用本文的文献

1
Central nervous system manifestations following vaccination against COVID-19.接种新型冠状病毒疫苗后的中枢神经系统表现。
Brain Behav Immun Health. 2024 May 3;38:100788. doi: 10.1016/j.bbih.2024.100788. eCollection 2024 Jul.
2
Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients.比较再生元新冠鸡尾酒疗法、瑞德西韦和法匹拉韦在降低住院COVID-19患者有创机械通气需求方面的疗效。
World J Clin Cases. 2023 Sep 16;11(26):6105-6121. doi: 10.12998/wjcc.v11.i26.6105.
3
Discovering associations between radiological features and COVID-19 patients' deterioration.

本文引用的文献

1
Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study.利用日本神户市门诊留存血清估计新型冠状病毒病(COVID-19)血清阳性率:一项横断面研究。
Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100747. doi: 10.1016/j.cegh.2021.100747. Epub 2021 Apr 19.
2
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
3
BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers.
发现放射学特征与新冠肺炎患者病情恶化之间的关联。
Health Sci Rep. 2023 May 8;6(9):e1257. doi: 10.1002/hsr2.1257. eCollection 2023 Sep.
4
Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients.比较卡西瑞维单抗和英夫维单抗、瑞德西韦及法匹拉韦对住院的新型冠状病毒肺炎患者病情进展和多器官功能影响的研究。
Open Med (Wars). 2023 Aug 9;18(1):20230768. doi: 10.1515/med-2023-0768. eCollection 2023.
5
A qualitative assessment of the adverse effects associated with COVID-19 vaccines: a study from Jordan.对与新冠疫苗相关的不良反应的定性评估:一项来自约旦的研究。
J Pharm Policy Pract. 2023 Aug 10;16(1):100. doi: 10.1186/s40545-023-00605-5.
6
A cyclic behavioral modeling aspect to understand the effects of vaccination and treatment on epidemic transmission dynamics.一种用于理解疫苗接种和治疗对传染病传播动力学影响的循环行为建模方面。
Sci Rep. 2023 May 23;13(1):8356. doi: 10.1038/s41598-023-35188-3.
7
Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients.比较卡西瑞维单抗和依姆德维单抗、瑞德西韦及法匹拉韦在住院的2019冠状病毒病患者中的疗效和安全性的临床研究。
J Clin Virol Plus. 2023 Jun;3(2):100151. doi: 10.1016/j.jcvp.2023.100151. Epub 2023 May 10.
8
A Systematic Review and Meta-Analysis Comparing the Diagnostic Accuracy Tests of COVID-19.一项比较新冠病毒病诊断准确性测试的系统评价和荟萃分析
Diagnostics (Basel). 2023 Apr 26;13(9):1549. doi: 10.3390/diagnostics13091549.
9
COVID-19 and hepatic injury: cellular and molecular mechanisms in diverse liver cells.COVID-19 与肝损伤:不同肝脏细胞中的细胞和分子机制。
World J Gastroenterol. 2023 Jan 21;29(3):425-449. doi: 10.3748/wjg.v29.i3.425.
10
Recent advances in point of care testing for COVID-19 detection.即时检测在 COVID-19 检测中的最新进展。
Biomed Pharmacother. 2022 Sep;153:113538. doi: 10.1016/j.biopha.2022.113538. Epub 2022 Aug 12.
BCG 疫苗接种史与不同医疗保健工作者人群 SARS-CoV-2 血清阳性率降低相关。
J Clin Invest. 2021 Jan 19;131(2). doi: 10.1172/JCI145157.
4
BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.巴西医护人员的卡介苗再接种以改善针对新冠病毒的先天免疫反应:一项随机对照试验研究方案的结构化总结
Trials. 2020 Oct 26;21(1):881. doi: 10.1186/s13063-020-04822-0.
5
Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest.在中西部一个中等规模城市中,接受康复期血浆治疗的新冠肺炎住院患者。
Transl Med Commun. 2020;5(1):17. doi: 10.1186/s41231-020-00068-9. Epub 2020 Oct 12.
6
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.两种基于 RNA 的新冠候选疫苗的安全性和免疫原性。
N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14.
7
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.《 老年人中新型冠状病毒 mRNA-1273 疫苗的安全性和免疫原性》
N Engl J Med. 2020 Dec 17;383(25):2427-2438. doi: 10.1056/NEJMoa2028436. Epub 2020 Sep 29.
8
Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly.激活:卡介苗疫苗接种预防老年人感染的随机临床试验。
Cell. 2020 Oct 15;183(2):315-323.e9. doi: 10.1016/j.cell.2020.08.051. Epub 2020 Sep 1.
9
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.瑞德西韦、洛匹那韦/利托那韦和氯喹/羟氯喹影响新型 SARS-CoV-2 的抗病毒机制研究进展。
Biomed Pharmacother. 2020 Nov;131:110668. doi: 10.1016/j.biopha.2020.110668. Epub 2020 Aug 24.
10
Tocilizumab in patients with severe COVID-19: a retrospective cohort study.托珠单抗治疗重症新型冠状病毒肺炎患者:一项回顾性队列研究
Lancet Rheumatol. 2020 Aug;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9. Epub 2020 Jun 24.